ClinicalTrials.gg
RecruitingNCT07419178GR-MPNUpdated Feb 18, 2026

A New Diagnostic Algorithm to Non-invasively Track Fibrotic Changes in Myeloproliferative Neoplasms Based on C-C Chemokine Receptor 2 Detection. From Flow Cytometry to the Development of Targeted Positron Emission Tomography Molecular Imaging. Pre-clinical Studies and First In-human Proof of Concept

An interventional study of Diagnosis of MPN subtypes in Myelofibrosis (MF), sponsored by Azienda Ospedaliero-Universitaria di Parma. Recruiting at 1 site in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-18.

Sponsored by Azienda Ospedaliero-Universitaria di Parma · Not applicable, Interventional, and Screening

How we know

From the registry’s dates

  • Registered 2 years 4 months after the study started (first participant enrolled Sep 2023, registered Jan 2026).
  • Started Sep 2023; still recruiting 3 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
265
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 101 studies in Primary Myelofibrosis with a site in Italy — 24 open to participants now, 43 under way, 11 of them phase 3. Primary Myelofibrosis · Italy.

Planned enrollment
19th of 83
265 · median 121
Started
2023
with 4 others
No phase
3 of 101
2 open now
Primary completion
2027-02
later than 20 of 42 live
Registered
95th of 101
by date

Among the 101 studies in Primary Myelofibrosis with a site in Italy, this one is the 19th largest by planned enrollment of the 83 interventional ones that give a count, is one of 5 that started in 2023, is one of 3 with no phase, reaches primary completion later than 20 of the 42 other live ones, and was the 95th registered.

Primary Myelofibrosis

628 studies on the registry are indexed under Primary Myelofibrosis; 126 are open to participants now.

Browse Primary Myelofibrosis studies →

Open to participants now

24 of the 101 studies in Primary Myelofibrosis with a site in Italy are open now. Recruiting first, the newest first:

18 more — sign in →

All 24 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 102 Primary Myelofibrosis studies recruiting now, 84 (82%) set no upper age limit and 13 (13%) stop at 75 or younger; 11 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 101 studies in Primary Myelofibrosis with a site in Italy, or all of them as a file.
02

Study summary

Chronic "Philadelphia-negative" myeloproliferative syndromes are chronic blood disorders. They include essential thrombocythemia, polycythemia vera, and myelofibrosis. Myelofibrosis may arise de novo ("primary myelofibrosis") or represent the evolution of essential thrombocythemia or polycythemia vera ("secondary myelofibrosis").

The myelofibrotic stage-characterized, as the name implies, by the presence of bone marrow fibrosis (deposition of scar-like tissue)-is generally associated with a more severe and symptomatic disease. To date, the only way to assess fibrotic progression in these disorders is bone marrow biopsy.

The aim of this project is to evaluate whether the identification, tracking, and quantification of cells expressing a specific receptor (CCR2), a selective biomarker of fibrosis, may allow early and non-invasive identification of the fibrotic stage of the disease through:

  • laboratory analysis on a blood sample (using flow cytometry)
  • use in PET-CT (positron emission tomography combined with computed tomography) of a tracer specific for the CCR2 receptor, capable of selectively binding to CCR2-expressing cells (⁶⁸Ga-DOTA-ECL1i).
Read the detailed description

It is well established that the presence of bone marrow fibrosis in Philadelphia-negative myeloproliferative neoplasms (MPNs) defines a more severe disease stage, with a worse prognosis and a high risk of leukemic transformation. Therefore, accurate allocation of each patient to the correct diagnostic category is essential for subsequent therapeutic planning, which may also include bone marrow transplantation for selected patients.

To date, the only method available to assess bone marrow fibrosis is histopathological analysis of the bone marrow, which inevitably requires an invasive procedure such as bone marrow biopsy.

The aim of this project is to evaluate whether tracking and quantification of CD34⁺CCR2⁺ cells through flow cytometry (FCM) on peripheral blood and functional imaging may represent a valid non-invasive tool for identifying the fibrotic stage of the disease, thus supporting clinicians at key diagnostic time points, such as:

At disease onset, in support of histopathology for differential diagnosis when morphological features alone may be ambiguous (e.g., ET vs prePMF, unclassifiable MPNs); During follow-up, in cases of suspected progression of ET/PV to secondary myelofibrosis (SMF), as a screening tool prior to bone marrow biopsy; As an alternative to bone marrow biopsy, when clinical conditions do not allow the procedure.

To this end, the project is structured around the following AIMS:

AIM 1 - Tracking of CD34⁺CCR2⁺ cells by flow cytometry as a diagnostic tool supporting histopathology in the differential diagnosis of MPN subtypes.

AIM 2 - Functional imaging of CCR2⁺ cells using the radioligand ⁶⁸Ga-DOTA-ECL1i in a murine model of myelofibrosis.

AIM 3 - Functional imaging of CCR2⁺ cells using the radioligand ⁶⁸Ga-DOTA-ECL1i in patients affected by MPNs.

03

Conditions studied

  • Myelofibrosis (MF)

Keywords

  • C-C chemokine receptor 2
  • Myeloproliferative neoplasms
  • PET
  • immunohystochemical assay
  • early detection of cancer
  • progression monitoring
  • therapy response monitoring
  • MRI
  • MRS
  • fluorescence
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of ET/PV/prePMF/overtPMF according to the WHO 2016 criteria and of SMF according to the IWG-MRT criteria (with histopathological data).
  • Age >= 18 yrs
  • performance status \<=3

Exclusion criteria

Exclusion Criteria:

  • Pregnancy/breastfeeding
  • Ongoing therapy with immunomodulatory drugs (JAK-inhibitors, interferon).
  • For PET imaging, patients should be off any cytoreductive treatment for at least 3 months.
  • Antiplatelet agents are allowed
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

05

Study design

Phase
Not applicable
Primary purpose
Screening
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
265 participants (estimated)

Study arms

  • Experimental
    MPN subtypes

    Patient will be tested for CCR2 expression on CD34+ cells in order to correlate imaging and flow-cytometry data.

    Diagnostic Test: Diagnosis of MPN subtypes

Interventions

  • Diagnostic testDiagnosis of MPN subtypes

    Non-invasive imaging method (PET/CT) and flow-cytometry

06

What researchers measure

Primary outcomes

  1. Percentage of circulating CD34+/CCR2+ cells

    Percentage of CD34+/CCR2+ cells among total CD34+ cells measured by flow cytometry in peripheral blood samples

    Time frame: At study enrollment

Secondary outcomes

  1. Bone marrow SUVmax on 68Ga-DOTA-ECL1i PET/CT

    Maximum standardized uptake value (SUVmax) of 68Ga-DOTA-ECL1i in bone marrow regions measured by PET/CT imaging

    Time frame: At imaging session

  2. Volume of active bone marrow on 68Ga-DOTA-ECL1i PET/CT

    Volume of interest with tracer uptake above mean liver uptake plus two standard deviations measured by PET/CT imaging

    Time frame: At imaging session

  3. Tracer uptake in extramedullary sites

    Standardized uptake value and signal-to-background ratio of 68Ga-DOTA-ECL1i in extramedullary sites measured by PET/CT imaging

    Time frame: At imaging session

07

Study locations

1 of 1 sites recruiting
  • Dipartimento di Medicina e Chirurgia
    Parma, Italy 43126, Italy
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Sep 2023 (actual). Primary completion is estimated for Feb 2027, 41 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 29, 2026
First posted
Feb 18, 2026
StartActual
Sep 5, 2023
Primary completionEst.
Feb 28, 2027
CompletionEst.
Apr 30, 2027
Last update
Feb 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07419178
Lead sponsor
Azienda Ospedaliero-Universitaria di Parma
Responsible party
Elena Masselli (Principal Investigator, Azienda Ospedaliero-Universitaria di Parma) — Principal investigator
First posted
Feb 18, 2026
Start date
Sep 5, 2023
Primary completion
Feb 28, 2027 (estimated)
Completion
Apr 30, 2027 (estimated)
Last update
Feb 18, 2026

Study contacts

Elena Masselli, MD, PhD
Contact
elena.masselli@unipr.it
+39 0521 906655

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion